Search Results - "Keipert, Peter E."

Refine Results
  1. 1
  2. 2

    Clinical Evaluation of MP4CO: A Phase 1b Escalating-Dose, Safety and Tolerability Study in Stable Adult Patients with Sickle Cell Disease by Keipert, Peter E

    “…MP4CO, developed by Sangart Inc. (San Diego, CA), is a pegylated human hemoglobin-based carbon monoxide (CO) delivery agent and oxygen therapeutic that has…”
    Get more information
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7

    Causes of metabolic acidosis in canine hemorrhagic shock: role of unmeasured ions by Bruegger, Dirk, Kemming, Gregor I, Jacob, Matthias, Meisner, Franz G, Wojtczyk, Christoph J, Packert, Kristian B, Keipert, Peter E, Faithfull, N Simon, Habler, Oliver P, Becker, Bernhard F, Rehm, Markus

    Published in Critical care (London, England) (01-01-2007)
    “…Metabolic acidosis during hemorrhagic shock is common and conventionally considered to be due to hyperlactatemia. There is increasing awareness, however, that…”
    Get full text
    Journal Article
  8. 8

    Randomized Safety Studies of Intravenous Perflubron Emulsion. I. Effects on Coagulation Function in Healthy Volunteers by Leese, Phillip T., Noveck, Robert J., Shorr, Jolene S., Woods, Catherine M., Flaim, Kathryn E., Keipert, Peter E.

    Published in Anesthesia and analgesia (01-10-2000)
    “…Previous perfluorocarbon (PFC) emulsions have been associated with transient adverse events (i.e., platelet activation, decreased platelet count, febrile…”
    Get full text
    Journal Article
  9. 9

    Randomized Safety Studies of Intravenous Perflubron Emulsion. II. Effects on Immune Function in Healthy Volunteers by Noveck, Robert J., Shannon, E. J., Leese, Phillip T., Shorr, Jolene S., Flaim, Kathryn E., Keipert, Peter E., Woods, Catherine M.

    Published in Anesthesia and analgesia (01-10-2000)
    “…Particle size distribution is a major determinant of particle clearance by the mononuclear phagocytic system and the potential for concomitant activation of…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Effect of hemoglobin- and Perflubron-based oxygen carriers on common clinical laboratory tests by Ma, Zhongmin, Monk, Terri G, Goodnough, Lawrence T, McClellan, Adrain, Gawryl, Maria, Clark, Terri, Moreira, Paulo, Keipert, Peter E, Scott, Mitchell G

    Published in Clinical chemistry (Baltimore, Md.) (01-09-1997)
    “…Polymerized hemoglobin solutions (Hb-based oxygen carriers; HBOCs) and a second-generation perfluorocarbon (PFC) emulsion (Perflubron) are in clinical trials…”
    Get full text
    Journal Article Conference Proceeding
  12. 12

    Perflubron emulsion (AF0144) augments harvesting of autologous blood: A phase II study in cardiac surgery by Hill, Steven E., Leone, Bruce J., Faithfull, N.Simon, Flaim, Kathy E., Keipert, Peter E., Newman, Mark F.

    “…Objective: To assess tolerance and preliminary efficacy of a perfluorocarbon emulsion (AF0144) used with acute normovolemic hemodilution to reduce allogeneic…”
    Get full text
    Journal Article
  13. 13

    Hemodilution and hyperoxia locally change distribution of regional pulmonary perfusion in dogs by Kleen, M, Habler, O, Hutter, J, Kemming, G, Podtschaske, A, Tiede, M, Welte, M, Keipert, P E, Batra, S, Faithfull, N S, Corso, C, Zwissler, B, Messmer, K

    Published in The American journal of physiology (01-02-1998)
    “…In seven anesthetized dogs, the effects of acute normovolemic hemodilution (ANH) to a hematocrit of 20 and 8% and the effects of hyperoxic ventilation (100%…”
    Get full text
    Journal Article
  14. 14

    Safety and Tolerability Of MP4CO: A Dose Escalation Study In Stable Patients With Sickle Cell Disease by Howard, Jo, Thein, Swee Lay, Galacteros, Frederic, Inati, Adlette, Reid, Marvin, Keipert, Peter E., Small, Tania N., Booth, Frank

    Published in Blood (15-11-2013)
    “…▪ Vaso-occlusive crises (VOC) remain the hallmark of Sickle Cell Disease (SCD) yet to date no agent has been approved to hasten the resolution of an acute…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20